SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: EX-99.1 2 v176570_ex99-1.htm
[EX-99.1 2 v176570_ex99-1.htm]
DSWL [DESWELL INDUSTRIES] CORRESP: (Original Filing)
[Deswell Industries, Inc. 17B, Edificio Comercial Rodrigues 599 Avenida da Praia Grande Macao, Special Administrative Region, PRC Tel: (853) 322096 Fax: (853) 323265 March 8, 2010 Via EDGAR Terence OBrien Re: Deswell Industries, Inc. (Deswell or the Company) Dear Mr. OBrien: Form 20-F for the Fiscal Year Ended March 31, 2009 Note 2 Summary of Significant Accounting Policies, page]
DSWL [DESWELL INDUSTRIES] CORRESP: Deswell Industries, Inc. 17B, Edificio Comercial Rodrigues 599
[Deswell Industries, Inc. 17B, Edificio Comercial Rodrigues 599 Avenida da Praia Grande Macao, Special Administrative Region, PRC Tel: (853) 322096 Fax: (853) 323265 March 8, 2010 Via EDGAR Terence OBrien Re: Deswell Industries, Inc. (Deswell or the Company) Dear Mr. OBrien: Form 20-F for the Fiscal Year Ended March 31, 2009 Note 2 Summary of Significant Accounting Policies, page]
MR [Mindray Medical International] 424B5: (Original Filing)
[CALCULATION OF REGISTRATION FEE Proposed maximum Proposed maximum Title of each class of Amount to be offering price pergregate offering Amount of securities to be registered RegisteredS price registration fee(3) ClassA ordinary shares, par value HK$0.001 per share(1) 4,600,000 (2) $ 38.20 $ 175,720,000 $ 12,528.84 (1) American depositary shares, orSs, issuable upon deposit of]
MR [Mindray Medical International] 424B5: CALCULATION OF REGISTRATION FEE Proposed maximum Proposed maximum
[CALCULATION OF REGISTRATION FEE Proposed maximum Proposed maximum Title of each class of Amount to be offering price pergregate offering Amount of securities to be registered RegisteredS price registration fee(3) ClassA ordinary shares, par value HK$0.001 per share(1) 4,600,000 (2) $ 38.20 $ 175,720,000 $ 12,528.84 (1) American depositary shares, orSs, issuable upon deposit of]
YGE [YINGLI GREEN ENERGY CO] 6-K: (Original Filing)
[Yingli Green Energy Reports Fourth Quarter and Full Year 2009 Results Fourth Quarter PV Module Shipments Increased by 15.7% Quarter over Quarter BAODING, China, March 8, 2010 Fourth Quarter 2009 Consolidated Financial and Operating Highlights Total net revenues were RMB 2,530.9 million (US$370.8 million) and PV module shipment volume increased by 15.7% quarter over quarter, reaching a historical high.] [Yingli Green Energy Announces 300 MW PANDA Mono-Crystalline BAODING, China, March 8, 2010 300 MW PANDA Mono-Crystalline Manufacturing Capacity Expansion at Baoding Headquarters Yingli Green Energy announced its plan to build PANDA mono-crystalline silicon-based manufacturing lines with annual production capacity of 300 MW in each of mono-crystalline ingots and wafers, cells and modules at its Baoding headquarters, through its]
MR [Mindray Medical International] 6-K: EXECUTION VERSION Mindray Medical International Limited 4,000,000 American
[EXECUTION VERSION Mindray Medical International Limited 4,000,000 American Depositary Shares (Par Value HK$0.001 Per Share) UNDERWRITINGREEMENT March3, 2010 JEFFERIES &MPANY, Ladies and Gentlemen: Introductory.mpany UnderwriterSs Ordinary Shares FirmSs OptionalSs OfferedSs Firm Shares Optional Shares Offered Shares Depositreement DepositaryRsmmission Base Prospectus] [4 March2010 th Mindray Medical International Limited DIRECT LINE: 852 2842 9500 Shenzhen 518057 Dear Sirs, Mindray Medical International Limitedmpany Registration Statement Securities Act Offering SharesSs We have actedecialyman legalunsel to Mindray Medical International Limited (the For the purposes of giving this opinion we have examinedpies of the following documents:] [[OMELVENY & MYERS LETTERHEAD] th Mindray Medical International Limited RE: 4,600,000 AMERICAN DEPOSITARY SHARES (THESS), REPRESENTING 4,600,000 CLASS A ORDINARY SHARES OF MINDRAY MEDICAL INTERNATIONAL LIMITED (THEMPANY) Ladies and Gentlemen: Respectfully submitted, EX-8.1 h04048exv8w1.htm 4 EX-8.1] [Mindray Medical International Limited Announces Pricing of a Public Offering of American Depositary Shares SHENZHEN, China, March4, 2010 Mindray Medical International Limited (NYSE: MR) (Mindray or thempany), a leading developer, manufacturer and marketer of medical devices worldwide, today announced the pricing of a public offering of 4,000,000 American depositary shares (ADSs), representing 4,000,000 ordinary shares]
YGE [YINGLI GREEN ENERGY CO] 6-K: Yingli Green Energy Reports Fourth Quarter and Full
[Yingli Green Energy Reports Fourth Quarter and Full Year 2009 Results Fourth Quarter PV Module Shipments Increased by 15.7% Quarter over Quarter BAODING, China, March 8, 2010 Fourth Quarter 2009 Consolidated Financial and Operating Highlights Total net revenues were RMB 2,530.9 million (US$370.8 million) and PV module shipment volume increased by 15.7% quarter over quarter, reaching a historical high.] [Yingli Green Energy Announces 300 MW PANDA Mono-Crystalline BAODING, China, March 8, 2010 300 MW PANDA Mono-Crystalline Manufacturing Capacity Expansion at Baoding Headquarters Yingli Green Energy announced its plan to build PANDA mono-crystalline silicon-based manufacturing lines with annual production capacity of 300 MW in each of mono-crystalline ingots and wafers, cells and modules at its Baoding headquarters, through its]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13G/A: (Original Filing)
[SCHEDULE 13G 3 (Amendment No. Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock 830884102 May 05, 2009 o x o * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13G/A: SCHEDULE 13G 3 (Amendment No. Skystar Bio-Pharmaceutical Company
[SCHEDULE 13G 3 (Amendment No. Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock 830884102 May 05, 2009 o x o * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures]
